The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Background
Cocaine use contines to be a significant public health problem world‐wide. However, despite substantial research efforts, no pharmacotherapies are approved for the treatment of cocaine use disorder (CUD).
Argument
Studies have identified positive signals for a range of medications for treating CUD. These include long‐acting amphetamine formulations, modafinil, topiramate, doxazosin and...
Background and Aims
Most US states have passed medical marijuana laws (MMLs), with great variation in program regulation impacting enrollment rates. We aimed to compare changes in rates of marijuana use, heavy use and cannabis use disorder across age groups while accounting for whether states enacted medicalized (highly regulated) or non‐medical mml programs.
Design
Difference‐in‐differences estimates...
AimsTo determine comorbidity patterns in treatment‐seeking substance use disorder (SUD) patients with and without adult attention deficit hyperactivity disorder (ADHD), with an emphasis on subgroups defined by ADHD subtype, taking into account differences related to gender and primary substance of abuse.
DesignData were obtained from the cross‐sectional International ADHD in Substance use disorder...
AimTo evaluate whether venlafaxine‐extended release (VEN‐XR) is an effective treatment for cannabis dependence with concurrent depressive disorders.
DesignThis was a randomized, 12‐week, double‐blind, placebo‐controlled trial of out‐patients (n = 103) with DSM‐IV cannabis dependence and major depressive disorder or dysthymia. Participants received up to 375 mg VEN‐XR on a fixed‐flexible schedule...
Aims There are no studies directly comparing self‐administration of methamphetamine and d‐amphetamine by humans. This study compared intranasal methamphetamine‐ and d‐amphetamine self‐administration and characterized the mood, performance and physiological effects produced by the drugs.
Design A randomized, double‐blind, placebo‐controlled, cross‐over study.
Setting An out‐patient research unit...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.